| Literature DB >> 35477727 |
Jeemyoung Kim1, Eun Jeong Gong1, Myeongsook Seo1, Jong Kyu Park1, Sang Jin Lee1, Koon Hee Han1, Young Don Kim1, Woo Jin Jeong1, Gab Jin Cheon1, Hyun Il Seo2.
Abstract
The optimal timing of endoscopy in patients with acute upper gastrointestinal bleeding (UGIB) remains controversial. In this study, we investigated the clinical outcomes of urgent endoscopy in patients with UGIB compared with elective endoscopy. From January 2016 to December 2018, consecutive patients who visited the emergency department and underwent endoscopy for clinical manifestations of acute UGIB, including variceal bleeding, were eligible. Urgent endoscopy (within 6 h) and elective endoscopy (after 6 h) were defined as the time taken to perform endoscopy after presentation to the emergency department. The primary outcome was mortality rate within 30 days. A total of 572 patients were included in the analysis. Urgent endoscopy was performed in 490 patients (85.7%). The 30-day mortality rate did not differ between the urgent and elective endoscopy groups (5.3% and 6.1%, p = 0.791). There was no difference regarding the recurrent bleeding rate, total amount of transfusion, or length of hospital between the groups. In multivariate analysis, age and the amount of transfusion were associated with mortality. Urgent endoscopy was not associated with a lower 30-day mortality rate compared with elective endoscopy in patients with acute UGIB.Entities:
Mesh:
Year: 2022 PMID: 35477727 PMCID: PMC9046398 DOI: 10.1038/s41598-022-10897-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Flowchart of the study. UGIB upper gastrointestinal bleeding.
Characteristics of the study population.
| Total (N = 572) | Urgent (n = 490) | Elective (n = 82) | ||
|---|---|---|---|---|
| Age, years | 63 (19–95) | 63 (21–95) | 62 (19–93) | 0.879 |
| Male | 366 (64.0) | 312 (63.7) | 54 (65.9) | 0.712 |
| Comorbidities | 461 (80.6) | 394 (80.4) | 67 (81.7) | 0.881 |
| Diabetes mellitus | 160 (28.0) | 135 (27.6) | 25 (30.5) | |
| Cerebrovascular accident | 63 (11.0) | 58 (11.8) | 5 (6.1) | |
| Vascular disease | 41 (7.2) | 34 (6.9) | 7 (8.5) | |
| Chronic kidney disease | 40 (7.0) | 32 (6.5) | 8 (9.8) | |
| Liver cirrhosis | 173 (30.2) | 153 (31.2) | 20 (24.4) | |
| Previous peptic ulcer | 73 (12.8) | 64 (13.1) | 9 (11.0) | 0.722 |
| Antithrombotic agents | 136 (23.8) | 116 (23.7) | 20 (24.4) | 0.889 |
| Aspirin | 100 (17.5) | 84 (17.1) | 16 (19.5) | |
| Clopidogrel | 42 (7.3) | 36 (7.3) | 6 (7.3) | |
| Dual antiplatelet therapy | 25 (4.4) | 21 (4.3) | 4 (4.9) | |
| Warfarin | 12 (2.1) | 11 (2.2) | 1 (1.2) | |
| DOAC | 16 (2.8) | 15 (3.1) | 1 (1.2) | |
| NSAID use | 42 (7.3) | 36 (7.3) | 6 (7.3) | 0.992 |
| 0.700 | ||||
| Hematemesis | 297 (51.9) | 258 (52.7) | 39 (47.6) | |
| Melena | 233 (40.7) | 196 (40.0) | 37 (45.1) | |
| Hematochezia | 42 (7.3) | 36 (7.3) | 6 (7.3) | |
| SBP, mmHg | 115 (51–226) | 114 (51–226) | 122 (67–194) | 0.015 |
| Heart rate, beats/min | 97 (35–165) | 98 (35–165) | 97 (50–149) | 0.806 |
| Hemoglobin, g/dL | 8.9 (2.6–19.1) | 9.1 (2.6–14.7) | 8.8 (3.2–19.1) | 0.339 |
| BUN/Cr ratio > 30 | 303 (53.0) | 256 (52.2) | 47 (57.3) | 0.406 |
| Platelet, × 103/µL | 195 (8–801) | 196 (8–801) | 185 (22–440) | 0.676 |
| Prothrombin time, % | 82 (4–137) | 81 (4–127) | 90 (8–137) | 0.008 |
| Time to endoscopy, hour | 2.4 (0.4–45.0) | 2.2 (0.4–5.9) | 9.9 (6.0–45.0) | < 0.001 |
| Glasgow-Blatchford score | 11 (0–18) | 11 (0–18) | 10 (0–16) | 0.334 |
Data are shown as median (range) or number (%).
BUN/Cr ratio ratio of blood urea nitrogen to creatinine, DOAC direct oral anticoagulant, NSAID non-steroidal anti-inflammatory drug, SBP systolic blood pressure.
Endoscopic findings and clinical outcomes.
| Total (N = 572) | Urgent (n = 490) | Elective (n = 82) | ||
|---|---|---|---|---|
| 0.569 | ||||
| Peptic ulcer | 310 (54.2) | 260 (53.1) | 50 (61.0) | |
| Malignancy | 31 (5.4) | 27 (5.5) | 4 (4.9) | |
| Mallory-Weiss syndrome | 49 (8.6) | 46 (9.4) | 3 (3.7) | |
| Gastroesophageal varix | 142 (24.8) | 124 (25.3) | 18 (22.0) | |
| Othersa | 40 (7.0) | 33 (6.7) | 7 (8.5) | |
| 338 (59.1) | 297 (60.0) | 41 (50.0) | 0.089 | |
| Thermocoagulation | 170 (29.7) | 147 (30.0) | 23 (28.0) | |
| Hemoclip | 22 (3.8) | 21 (4.3) | 1 (1.2) | |
| Injection | 31 (5.4) | 29 (5.9) | 2 (2.4) | |
| Band ligation | 139 (24.3) | 122 (24.9) | 17 (20.7) | |
| Combination | 42 (7.3) | 37 (7.6) | 5 (6.1) | |
| Embolization | 3 (0.5) | 3 (0.6) | 0 | 1.000 |
| RBC transfusion, unit | 2 (0–16) | 2 (0–16) | 2 (0–8) | 0.346 |
| Rebleeding (n = 571) | 34 (6.0) | 29 (5.9) | 5 (6.1) | 1.000 |
| Mortality | 31 (5.4) | 26 (5.3) | 5 (6.1) | 0.791 |
| Hospital stay, days | 6 (1–128) | 6 (1–128) | 6 (1–86) | 0.401 |
aOthers include marginal ulcer, acute gastric mucosal lesion, angioectasia, tuberculosis, esophageal ulcer, jejunal ulcer, gastrointestinal stromal tumor, and neuroendocrine tumor.
Figure 2Mortality and recurrent bleeding rates within 30 days. (A) The mortality rate did not differ between the urgent (≤ 6 h from presentation) and elective (> 6 h from presentation) endoscopy groups, (B) the recurrent bleeding rate did not differ between the groups.
Factors associated with mortality.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Age | 1.035 | 1.006–1.064 | 0.017 | 1.038 | 1.008–1.069 | 0.013 |
| Comorbidity | 3.659 | 0.860–15.569 | 0.079 | |||
| Variceal bleeding | 1.997 | 0.944–4.223 | 0.070 | |||
| Glasgow-Blatchford score | 1.115 | 0.999–1.243 | 0.051 | 1.045 | 0.926–1.180 | 0.476 |
| RBC transfusion | 1.391 | 1.194–1.621 | < 0.001 | 1.384 | 1.178–1.627 | < 0.001 |
| Urgent endoscopy | 0.863 | 0.322–2.335 | 0.863 | |||
BUN/Cr ratio ratio of blood urea nitrogen to creatinine, CI confidence interval, OR odds ratio, RBC red blood cell.